First Quarter 2018 Investor Presentation
Investor Presentation
First three months of 2018
Novo Nordisk holds ~35% volume market share of the
basal market in the USA
Slide 8
Weekly TRX volume market shares¹ in the USA
-
glargine U100
Basal volume
TRX MS
70%
60%
50%
40%
30%
20%
10%
0%
Mar
2016
NN Total Basal
TresibaⓇ
LevemirⓇ
glargine U300
biosimilar glargine U100
42.2%
34.8%
22.8%
11.8%
8.5%
8.4%
Mar
2018
TresibaⓇ launch in the USA
• TresibaⓇ TRX volume market share is now 11.8%
• Main market share driver in Q1 2018 has been the
formulary change at CVS part D¹
⚫ TresibaⓇ formulary access is now estimated to be around
80%² for Commercial and Medicare Part D combined,
following formulary access on United Health Care Part D
⚫ TresibaⓇ label in the USA updated to include cardiovascular
safety data and 40% reduction of severe hypoglycaemic
events compared to insulin glargine U100. The updated
TresibaⓇ label was launched mid-April 2018 in the USA
Note: The graph does not show NPH, which accounts for the residual market share
Source: IQVIA weekly Xponent Plantrak, 23 March 2018
¹Excludes Medicaid that represents ~12% of retail basal market volume and basal insulin and GLP-1
combination products such as XultophyⓇ
TRX volume: Insulin volume in mega units (MU) associated with total number of prescriptions;
MS: Market share
Source: IQVIA weekly Xponent Plantrak, 23 March, 2018
1 CVS formulary Silverscript
2 Projected access calculated from VANTAGE FingerTip Formulary bridge February 2018,
week ending 2 March 2018.
novo nordiskView entire presentation